Dr. Dobrin Nedelkov, President

Dr. Nedelkov is a proven leader in clinical MS assays and technology development, with 20+ years scientific and management experience. Dr. Nedelkov received his Ph.D. in Biochemistry from Arizona State University in 1997. After a year as a Postdoctoral Associate at Yale University, Dr. Nedelkov joined Intrinsic Bioprobes where over the span of 15 years he progressed through the ranks to ultimately become Scientific Director and CEO of the company, leading the early commercialization efforts in technology development for targeted proteomics and protein biomarkers. Following an acquisition by Thermo Scientific, Dr. Nedelkov joined the Biodesign Institute at Arizona State University in 2013 as a group leader of the Molecular Biomarkers Unit, focusing on proteoform biomarker discovery, validation, and translation. In 2017 Dr. Nedelkov started Isoformix with the goal of translating MS protein tests into the clinic.  Dr. Nedelkov has authored over 100 peer reviewed scientific articles, presented at more than 60 scientific meetings, has 4 issued patents, and has served as a principal investigator on numerous NIH grants.   

Dr. Hu is principal scientist on the protein glycoforms project at Isoformix. Dr. Hu obtained her Ph.D. in Biochemistry from Arizona State University studying protein glycans and working on methodology development for glycan node analysis in whole biospecimens. In 2019 Dr. Hu joined Isoformix Inc. and started rigorous method development for analysis of glycoforms of apolipoproteins such as apolipoprotein C-III (apoC-III) and apolipoprotein E (apoE). Dr. Hu is currently implementing these methods along with statistical approaches in discovering and validating apoE isoform-specific glycosylation, with important implications to understanding how the apoE4 allele increases the risk of Alzheimer’s disease.